NCT06057922 2026-03-12
A Study YL201 in Patients With Selected Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Active not recruiting
Clinical Trials
24 trialsNCT06367751 2026-03-11
LIQPLAT
University Hospital, Basel, Switzerland
Phase NA Active not recruiting
NCT06685068 2026-03-03
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT04735978 2026-02-27
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
Replimune Inc.
Phase 1 Active not recruiting
NCT06422520 2026-02-23
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Active not recruiting
NCT04649385 2026-02-20
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Active not recruiting
NCT04083976 2026-02-04
RAGNAR
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT05518045 2026-02-04
A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors
LaNova Medicines Limited
Phase 1/2 Active not recruiting
NCT05352750 2026-02-03
Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors
Sonnet BioTherapeutics
Phase 1 Active not recruiting
NCT05744427 2026-02-02
Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2 Active not recruiting
NCT06993116 2026-01-28
A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 1 Active not recruiting
NCT05163041 2026-01-15
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
BicycleTx Limited
Phase 1/2 Active not recruiting
NCT06328673 2025-12-24
A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
D2M Biotherapeutics Inc.
Phase 1 Active not recruiting
NCT06345482 2025-11-20
A Study of MHB039A for Advanced Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2 Active not recruiting
NCT06373406 2025-11-19
A Study of MHB036C for Advanced Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2 Active not recruiting
NCT06143007 2025-11-17
A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors
Broadenbio Ltd., Co.
Phase 1 Active not recruiting
NCT06260774 2025-10-02
Study of TTX-MC138 in Subjects With Advanced Solid Tumors
TransCode Therapeutics
Phase 1/2 Active not recruiting
NCT06480240 2025-08-08
A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors
OBI Pharma, Inc
Phase 1/2 Active not recruiting
NCT06428500 2025-07-25
QTX3046 in Patients With KRAS G12D Mutations
Quanta Therapeutics
Phase 1 Active not recruiting
NCT04322006 2025-05-22
A Phase I/II Study of TJ004309 for Advanced Solid Tumor
TJ Biopharma Co., Ltd.
Phase 1/2 Active not recruiting
NCT04751786 2025-04-04
PRECIOUS-01
Radboud University Medical Center
Phase 1 Active not recruiting
NCT05990452 2024-11-21
Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Active not recruiting
NCT05278546 2024-11-12
A Study of ILB2109 in Patients With Advanced Solid Malignancies
Innolake Biopharm
Phase 1 Active not recruiting
NCT05765032 2024-09-26
Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Active not recruiting